research Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
Search
for
Sort by
Research
450-480 / 1000+ results 
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research 43755 Rapid Reduction and Strict Complete Response in Itch With Oral Difelikefalin in Subjects With Notalgia Paresthetica and Moderate-to-Severe Pruritus
Oral difelikefalin significantly reduces itch in notalgia paresthetica.
research JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
research 31810 The National Paediatric Alopecia Areata Registry in Russia: An overview
The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Race and Alopecia Areata amongst US Women
Black and Hispanic women are more likely to have alopecia areata than white women.
research Current Treatment of Alopecia Areata
There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.
research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
research Ischemic modified albumin as a new biomarker in predicting of oxidative stress in alopecia areata
Ischemic modified albumin could be a new indicator of oxidative stress in people with alopecia areata.
research From joint pains to hair gains: baricitinib’s double duty for rheumatoid arthritis and alopecia areata
Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research General practitioners’ knowledge and practices related to alopecia areata in Qassim region, Saudi Arabia
General practitioners in Qassim have satisfactory knowledge of alopecia areata but need more education to address gaps and misconceptions.
research Emerging role of baricitinib in dermatology practice: All we need to know!
Baricitinib effectively treats certain skin conditions but may have serious side effects.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Elevated serum heat shock protein-70 and interleukin-15: prognostic biomarkers correlating with clinical severity and diagnostic efficacy in active alopecia areata
High levels of HSP70 and IL-15 are linked to more severe alopecia areata.
research The Legal Status and Liability of the OH Professional
OH professionals must clearly understand their role and responsibilities to avoid legal issues.
research Alopecia areata: current concepts
New treatments for alopecia areata show promise but need ongoing use and have infection risks.
research Hypersensitivity Reactions to Anticoagulant Drugs
Allergic reactions to blood thinners are rare but can be serious, requiring careful management and alternative treatments.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research Trichohyalin is a Potential Major Autoantigen in Human Alopecia Areata
Trichohyalin may trigger the immune response causing alopecia areata.
research One of the best treatments for alopecia areata remains unpublished
DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
research Consensus Document on the Clinical Management of Alopecia Areata: Recommendations from the Spanish Hair Research Group of the Spanish Academy of Dermatology and Venerology)
JAK inhibitors are recommended for severe alopecia areata if corticosteroids fail.
research JAK inhibitors for alopecia areata: a systematic review and meta‐analysis
JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
research Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with AIRE gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
Ruxolitinib helped a patient with alopecia areata regrow hair.
research Management of Indralupta with Pracchana- A Case Study
Ayurvedic treatment effectively improved patchy hair loss in a 25-year-old male.
research Drug-Induced Alopecia Areata From Upadacitinib
Upadacitinib may cause hair loss.
research Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment
The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.